Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2 cancer vaccine - BioLife Science

Drug Profile

HER2 cancer vaccine - BioLife Science

Alternative Names: Her VAXX; HER-Vaxx; IMU-131; PEV 6A; PEV6

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioLife Science; Pevion Biotech
  • Developer Imugene; Pevion Biotech
  • Class Cancer vaccines; Peptides
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer; Oesophageal cancer
  • No development reported Breast cancer

Most Recent Events

  • 01 Oct 2019 Updated efficacy data from a phase I/II trial in Gastric cancer and Oesophageal cancer released by Imugene
  • 31 May 2019 Updated adverse events and efficacy data from a phase I/II trial in Gastric cancer and Oesophageal cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology
  • 28 May 2019 No recent reports of development identified for preclinical development in Gastric-cancer in Austria (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top